Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies

Todd Schlesinger; Neal Bhatia; Brian  Berman; Ayman Grada; Laura Padulles; Francisco Hernandez; David Cutler; Mark Lebwohl

doi:10.25251/skin.6.supp.26

Todd Schlesinger

Clinical Research Center of The Carolinas

Neal Bhatia

Therapeutics Clinical Research, San Diego, CA, USA

Brian Berman

University of Miami Miller School of Medicine

Ayman Grada

Almirall

Laura Padulles

Almirall, Barcelona, Spain

Francisco Hernandez

Almirall, Spain

David Cutler

Athenex

Mark Lebwohl

Mount Sinai

Keywords

actinic keratosis

Abstract

N/A

References

1. Blauvelt A et al. New Engl J Med 2021;384:512-20.

Poster PDF

Published

Mar 4, 2022

DOI https://doi.org/10.25251/skin.6.supp.26

How to Cite

Schlesinger, T., Bhatia, N., Berman, B. ., Grada, A., Padulles, L., Hernandez, F., Cutler, D., & Lebwohl, M. (2022). Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies. SKIN The Journal of Cutaneous Medicine, 6(2), s26. https://doi.org/10.25251/skin.6.supp.26

Issue

Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

Section

Skin Cancer

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Mark Lebwohl, Kim A Papp, Jashin J Wu, Andrew Blauvelt, Alan Menter, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel, Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Todd Schlesinger, Leon Kircik, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Kenneth B Gordon, Richard G Langley, Richard B Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Natalie Nunez Gomez, Diamant Thaçi, Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Mark Lebwohl, Bruce Strober, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Nehal N. Mehta, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Alan Menter, Jeff Sobell, Jonathan I Silverberg, Mark Lebwohl, Shipra Rastogi, Radhakrishnan Pillai, Robert J Israel, Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Umair Khan, Nahla Shihab, Robert G Phelps, Mark Lebwohl, Successful Treatment of Pityriasis Rubra Pilaris with Brodalumab , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 2 (2020)
Brian Berman, Neal Bhatia, Daniel Piacquadio, Anna Houlihan, Daniel Siegel, Efficacy of ALA–PDT in the Treatment of Actinic Keratoses on the Upper Extremities: A Post Hoc Analysis of a Phase 3, Randomized, Vehicle-Controlled Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Emmy Graber, Hilary Baldwin, Julie C Harper, Linda Stein Gold, Ayman Grada, Andrew F Alexis, Adelaide A Hebert, Richard G Fried, Evan A Rieder, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Leon Kircik, Patient Reported Outcomes (PROs) and Investigator Global assessment (IGA) of Acne Vulgaris among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in real-world community practices across the U.S. (PROSES Study) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Leon Kircik, Todd Schlesinger, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Matthias Augustin, Jolanta Weglowska, Mark Lebwohl, Carle Paul, Vincent Piquet, Howard Sofen, Andrew Blauvelt, Daniel Burge, Luke Peterson, Janice Drew, Robert Rollen, Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas

<< < 4 5 6 7 8 9 10 11 12 13 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)